In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Avoiding specific region of brain during whole-brain radiotherapy prevents memory loss
NCI Cancer Center News
(Posted: 09/25/2013) - Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according to research presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting by researchers from the University of Wisconsin School of Medicine and Public Health, home of the UW Paul P. Carbone Comprehensive Cancer Center.

Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk prostate cancer
NCI Cancer Center News
(Posted: 09/25/2013) - A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting by researchers from the Mayo Clinic. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total androgen suppression (TAS).

Functional disability high among newly diagnosed older breast cancer patients
NCI Cancer Center News
(Posted: 09/23/2013) - Many older women with newly diagnosed breast cancer have difficulty accomplishing daily tasks, and African-Americans seem to be disproportionately affected. Those are the findings of a new study published early online in CANCER by researchers from the Case Western Reserve University School of Medicine and University Hospitals Case Medical Center in Cleveland (home of the Case Comprehensive Cancer Center), a peer-reviewed journal of the American Cancer Society. The study's results suggest that many breast cancer patients could benefit from receiving therapy to improve their physical function.

Researchers identify biomarker for smoker's lung cancer
NCI Cancer Center News
(Posted: 09/23/2013) - Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.

USC scientists ID protein that regulates cellular trafficking, potential for anti-cancer therapy
NCI Cancer Center News
(Posted: 09/23/2013) - Molecular microbiologists at the University of Southern California (home of the USC Norris Comprehensive Cancer Center) have uncovered intricate regulatory mechanisms within the cell that could lead to novel therapeutics for the treatment of cancer and other diseases. Their findings, which have long-standing significance in the basic understanding of cell biology, appear in the journal Nature Cell Biology.

Adult cancer patients younger than 50 with limited brain mets have improved overall survival after stereotactic radiosurgery alone
NCI Cancer Center News
(Posted: 09/23/2013) - When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Younger patients (under 50 years old) were also found to be at no greater risk of new brain metastases developing despite omission of WBRT. The study included authors from the University of Southern California (home of the USC Norris Comprehensive Cancer Center) and the University of Texas MD Anderson Cancer Center.

Proton therapy is a cost-effective treatment for pediatric brain tumor patients
NCI Cancer Center News
(Posted: 09/23/2013) - Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that mainly affect children, when compared to standard photon radiation therapy, according to research presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting by researchers from the Mount Auburn Hospital, the teaching hospital of Harvard Medical School (a component of the Dana-Farber Cancer Institute).

Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
NCI Cancer Center News
(Posted: 09/23/2013) - Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been shown in a past trial of 31 patients to decrease diarrhea during pelvic RT (Killic 2001). Sulfasalazine does not reduce diarrhea, according to research presented at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting by researchers from the Mayo Medical School and the Mayo Clinic. The study also determined that the medication may be associated with a higher risk of diarrhea than placebo.

Researchers at Washington U develop new models of drug-resistant breast cancer that hint at better treatments
NCI Cancer Center News
(Posted: 09/20/2013) - Researchers at Washington University School of Medicine in St. Louis have shown that human breast tumors transplanted into mice are excellent models of metastatic cancer and could be valuable tools in the search for better treatments.

Avon Foundation for Women, NIH, and The Center for Advancing Innovation launch start-up challenge to advance breast cancer biomedical inventions; student and entrepreneur mentor teams to develop strategic business plan and launch biotech start-up
NCI and Partners Release
(Posted: 09/19/2013) - A world-wide competition to bring emerging breast cancer technologies to market is being launched by the Avon Foundation for Women, in partnership with NCI and the Center for Advancing Innovation.

< Previous  20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40  Next >